Suchergebnisse - "Deschatelets, Pascal"

Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal Hemoglobinuria von Hillmen, Peter, Szer, Jeff, Weitz, Ilene, Röth, Alexander, Höchsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, de Castro, Carlos, Nishimori, Hisakazu, Tan, Lisa, Hamdani, Mohamed, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Ajayi, Temitayo, Risitano, Antonio, de la Tour, Régis Peffault

“… Anemia associated with PNH is caused by hemolysis. The C5 inhibitor eculizumab blocks intravascular hemolysis, but anemia often persists owing to extravascular …”
Volltext

Inside-Out of Complement in Cancer von Kolev, Martin, Das, Madhumita, Gerber, Monica, Baver, Scott, Deschatelets, Pascal, Markiewski, Maciej M.

“… The role of complement in cancer has received increasing attention over the last decade. Recent studies provide compelling evidence that complement accelerates …”
Volltext

Pre-existing humoral immunity and complement pathway contribute to immunogenicity of adeno-associated virus (AAV) vector in human blood von Smith, Corinne J., Ross, Nikki, Kamal, Ali, Kim, Kevin Y., Kropf, Elizabeth, Deschatelets, Pascal, Francois, Cedric, Quinn, William J., Singh, Inderpal, Majowicz, Anna, Mingozzi, Federico, Kuranda, Klaudia

“… AAV gene transfer is a promising treatment for many patients with life-threatening genetic diseases. However, host immune response to the vector poses a …”
Volltext

The future of complement therapeutics von Kolev, Martin, Rao, Kollu Nageswara, Yeh, Michael, Parikh, Atman, Deschatelets, Pascal

“… Complement is both evolutionary and scientifically old. It predates the adaptive immunity by some 600 million years and was first described in 1905 by Jules …”
Volltext

Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase 3, active-comparator, controlled trial von de Latour, Régis Peffault, Szer, Jeff, Weitz, Ilene C, Röth, Alexander, Höchsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, de Castro, Carlos M, Nishimori, Hisakazu, Ajayi, Temitayo, Al-Adhami, Mohammed, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Risitano, Antonio M, Hillmen, Peter

“… In the PEGASUS trial, the complement C3 inhibitor, pegcetacoplan, showed superiority to eculizumab in improving haematological outcomes in adult patients with …”
Weitere Angaben

Results of the Pegasus Phase 3 Randomized Trial Demonstrating Superiority of the C3 Inhibitor, Pegcetacoplan, Compared to Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria von Castro, Carlos de, Hillmen, Peter, Szer, Jeff, Weitz, Ilene, Röth, Alexander, Hoechsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, Nishimori, Hisakazu, Tan, Lisa, Hamdani, Mohamed, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Risitano, Antonio, Latour, Regis Peffault de

Volltext

Plain language summary: treatment of paroxysmal nocturnal hemoglobinuria with pegcetacoplan for 48 weeks (PEGASUS study) von de Latour, Régis Peffault, Szer, Jeff, Weitz, Ilene, Röth, Alexander, Höchsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, Castro, Carlos de, Nishimori, Hisakazu, Al-Adhami, Mohammed, Deschatelets, Pascal, Francois, Cedric, Risitano, Antonio, Hillmen, Peter

Volltext

With complements: C3 inhibition in the clinic von Kolev, Martin, Barbour, Tara, Baver, Scott, Francois, Cedric, Deschatelets, Pascal

“… Summary C3 is a key complement protein, located at the nexus of all complement activation pathways. Extracellular, tissue, cell‐derived, and intracellular C3 …”
Volltext

Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors von Hillmen, Peter, Horneff, Regina, Yeh, Michael, Kolev, Martin, Deschatelets, Pascal

“… Paroxysmal nocturnal hemoglobinuria (PNH) is a rare and potentially life-threatening hematologic disorder caused by a somatic mutation in a relevant portion of …”
Volltext

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial von Liao, David S, Grossi, Federico V, El Mehdi, Delphine, Gerber, Monica R, Brown, David M, Heier, Jeffrey S, Wykoff, Charles C, Singerman, Lawrence J, Abraham, Prema, Grassmann, Felix, Nuernberg, Peter, Weber, Bernhard H F, Deschatelets, Pascal, Kim, Robert Y, Chung, Carol Y, Ribeiro, Ramiro M, Hamdani, Mohamed, Rosenfeld, Philip J, Boyer, David S, Slakter, Jason S, Francois, Cedric G

“… Geographic atrophy (GA), a late stage of age-related macular degeneration (AMD), is a major cause of blindness. Even while central visual acuity remains …”
Weitere Angaben

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab von Castro, Carlos, Grossi, Federico, Weitz, Ilene Ceil, Maciejewski, Jaroslaw, Sharma, Vivek, Roman, Eloy, Brodsky, Robert A., Tan, Lisa, Di Casoli, Carl, El Mehdi, Delphine, Deschatelets, Pascal, Francois, Cedric

“… Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, life‐threatening hematologic disease characterized by chronic complement‐mediated hemolysis and …”
Volltext

Complement signaling as a T-cell checkpoint in the tumor microenvironment von Giridharan, Thejaswini, Suzuki, Sora, Nazmul Khan, A.N.M., Emmons, Tiffany, Yaffe, Michael, Lun, Xiaokang, Joughin, Brian, Kolev, Martin, Deschatelets, Pascal, Kemper, Claudia, McGray, A.J.R., Zsiros, Emese, Segal, Brahm

“… Durable anti-tumor immunity requires the recruitment, infiltration, and activation of antigen-directed T-cells within the tumor. Cancer immunotherapy is …”
Volltext

Effects of complement C3/C3b inhibition on control of malignant effusions and neutrophil phenotypes in patients with recurrent epithelial ovarian cancer: Interim analysis of a phase 2 clinical trial von Zsiros, Emese, Nazmul Khan, A.N.M., Giridharan, Thejaswini, Suzuki, Sora, DeJohn, Celia, Hess, Suzanne, Mager, Katherine, Werner, Sarah, McLean, Karen, Gaulin, Nicole, Frederick, Peter, Puzanov, Igor, Kolev, Martin, Deschatelets, Pascal, Segal, Brahm

“… Malignant effusions (ME) can promote metastatic seeding and are challenging to manage. Using ME from patients with epithelial ovarian cancer (OC) and other …”
Volltext

Pegcetacoplan controls hemolysis in complement inhibitor–naive patients with paroxysmal nocturnal hemoglobinuria von Wong, Raymond Siu Ming, Navarro-Cabrera, Juan Ramon, Comia, Narcisa Sonia, Goh, Yeow Tee, Idrobo, Henry, Kongkabpan, Daolada, Gómez-Almaguer, David, Al-Adhami, Mohammed, Ajayi, Temitayo, Alvarenga, Paulo, Savage, Jessica, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Dumagay, Teresita

“… •Complement inhibitor–naive patients with PNH had greater hemoglobin stabilization and LDH reduction with pegcetacoplan vs control.•Pegcetacoplan’s …”
Volltext

Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria von Wong, Raymond S. M., Pullon, Humphrey W. H., Amine, Ismail, Bogdanovic, Andrija, Deschatelets, Pascal, Francois, Cedric G., Ignatova, Kalina, Issaragrisil, Surapol, Niparuck, Pimjai, Numbenjapon, Tontanai, Roman, Eloy, Sathar, Jameela, Xu, Raymond, Al-Adhami, Mohammed, Tan, Lisa, Tse, Eric, Grossi, Federico V.

“… Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired hematologic disorder characterized by complement-mediated hemolysis. C5 inhibitors …”
Volltext

3113 – FORTY-EIGHT WEEK EFFICACY AND SAFETY OF PEGCETACOPLAN IN ADULT PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND SUBOPTIMAL RESPONSE TO PRIOR ECULIZUMAB TREATMENT von de Latour, Régis Peffault, Szer, Jeffrey, Weitz, Ilene, Röth, Alexander, Höchsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, de Castro, Carlos, Nishimori, Hisakazu, Tan, Lisa, Al-Adhami, Mohammed, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Risitano, Antonio, Hillmen, Peter

“… Pegcetacoplan (PEG) is a C3 complement inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). PEG was superior to eculizumab (ECU; …”
Volltext

Pegcetacoplan compared with supportive care for 26 weeks for participants with paroxysmal nocturnal hemoglobinuria: a plain language summary von Ming Wong, Raymond Siu, Navarro-Cabrera, Juan Ramon, Comia, Narcisa Sonia, Goh, Yeow Tee, Idrobo, Henry, Kongkabpan, Daolada, Gómez-Almaguer, David, Al-Adhami, Mohammed, Ajayi, Temitayo, Alvarenga, Paulo, Savage, Jessica, Deschatelets, Pascal, Francois, Cedric, Grossi, Federico, Dumagay, Teresita

“… In the PRINCE study, adults with paroxysmal nocturnal hemoglobinuria (PNH) who had not recently taken a C5 complement inhibitor medicine received pegcetacoplan …”
Volltext

Plain language summary: treatment of paroxysmal nocturnal hemoglobinuria with pegcetacoplan for 48 weeks (PEGASUS study) von de Latour, Régis Peffault, Szer, Jeff, Weitz, Ilene, Röth, Alexander, Höchsmann, Britta, Panse, Jens, Usuki, Kensuke, Griffin, Morag, Kiladjian, Jean-Jacques, Castro, Carlos de, Nishimori, Hisakazu, Al-Adhami, Mohammed, Deschatelets, Pascal, Francois, Cedric, Risitano, Antonio, Hillmen, Peter

“… The PEGASUS study found that after 16 weeks, pegcetacoplan increased hemoglobin better than eculizumab did in adults with PNH. During the PEGASUS open-label …”
Volltext

APL-2, a complement C3 inhibitor, may potentially reduce both intravascular and extravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria von Mehdi, Delphine El, Grossi, Federico V., Deschatelets, Pascal, Pullon, Humphrey, Tan, Lisa, Vega, Carolina A., Francois, Cedric G.

Volltext

Pegcetacoplan for the treatment of geographic atrophy due to age-related macular degeneration: a plain language summary of OAKS and DERBY clinical studies von Heier, Jeffrey S, Lad, Eleonora M, Holz, Frank G, Rosenfeld, Philip J, Guymer, Robyn H, Boyer, David, Grossi, Federico, Baumal, Caroline R, Korobelnik, Jean-Francois, Slakter, Jason S, Waheed, Nadia K, Metlapally, Ravi, Pearce, Ian, Steinle, Nathan, Francone, Anibal A, Hu, Allen, Lally, David R, Deschatelets, Pascal, Francois, Cedric, Bliss, Caleb, Staurenghi, Giovanni, Monés, Jordi, Singh, Rishi P, Ribeiro, Ramiro, Wykoff, Charles C

“… What is this summary about?This is a summary of the results of 2 clinical studies , called OAKS and DERBY, that tested a medicine called pegcetacoplan …”
Weitere Angaben